Niagen Bioscience, Inc. (NAGE) - What Are Brokerages Saying About This Stock?

Key Points

• Analyst sentiment is broadly positive: Six brokerages give Niagen Bioscience an average “Buy” rating, with a consensus 12-month price target of $8.50.
• Recent price targets have been cut: Canaccord lowered its target from $9 to $7, and Freedom Broker reduced its target from $8.50 to $6; both maintained “Buy” ratings.
• NAGE opened at $2.13, near its 12-month low of $2.04. The company reported quarterly EPS of -$0.01, matching consensus, and revenue of $27.19 million.

Shares of Niagen Bioscience, Inc. (NASDAQ:NAGE - Get Free Report) have been assigned an average rating of "Buy" from the six brokerages that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $8.50.

NAGE has been the topic of a number of analyst reports. Canaccord Genuity Group cut their price objective on shares of Niagen Bioscience from $9.00 to $7.00 and set a "buy" rating on the stock in a report on Friday, November 6th. Freedom Broker lowered their target price on shares of Niagen Bioscience from $8.50 to $6.00 and set a "buy" rating for the company in a report on Friday, November 6th. Weiss Ratings lowered shares of Niagen Bioscience from a "hold (c)" rating to a "hold (c-)" rating in a research report on Monday. Finally, Roth Capital restated a "buy" rating on shares of Niagen Bioscience in a report on Wednesday, August 5th.

Institutional Investors Weigh In On Niagen Bioscience

Hedge funds have recently modified their holdings of the stock. SteelPeak Wealth LLC purchased a new position in shares of Niagen Bioscience in the first quarter worth about $14,875,000. Arrowstreet Capital Limited Partnership lifted its position in shares of Niagen Bioscience by 47.1% during the first quarter. Arrowstreet Capital Limited Partnership now owns 2,378,437 shares of the company's stock worth $10,489,000 after acquiring an additional 761,685 shares in the last quarter. Tieton Capital Management LLC purchased a new stake in shares of Niagen Bioscience during the second quarter worth $6,407,000. Renaissance Technologies LLC boosted its holdings in shares of Niagen Bioscience by 45.4% in the first quarter. Renaissance Technologies LLC now owns 1,328,843 shares of the company's stock worth $5,860,000 after acquiring an additional 414,725 shares during the period. Finally, Dimensional Fund Advisors LP grew its position in shares of Niagen Bioscience by 16.4% in the first quarter. Dimensional Fund Advisors LP now owns 1,071,133 shares of the company's stock valued at $4,723,000 after purchasing an additional 150,763 shares in the last quarter. Institutional investors own 15.41% of the company's stock.

Niagen Bioscience Stock Up 1.4%

Niagen Bioscience stock opened at $2.13 on Friday. The company has a market capitalization of $168.70 million, a PE ratio of 17.75 and a beta of 2.12. Niagen Bioscience has a 12-month low of $2.04 and a 12-month high of $7.28. The firm's fifty day moving average is $2.68 and its 200 day moving average is $3.75.

Niagen Bioscience (NASDAQ:NAGE - Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The company reported ($0.01) EPS for the quarter, hitting analysts' consensus estimates of ($0.01). The business had revenue of $27.19 million during the quarter. Niagen Bioscience had a net margin of 8.37% and a return on equity of 10.18%. Sell-side analysts expect that Niagen Bioscience will post 0.04 EPS for the current fiscal year.

About Niagen Bioscience

Niagen Bioscience, Inc. develops and markets products based on nicotinamide riboside (NR), a form of vitamin B3 studied for its role in supporting the body's production of NAD+. Its offerings include Tru Niagen, a consumer dietary supplement, and Niagen, a branded NR ingredient supplied to other businesses. The company also conducts and supports research on NR, NAD+ and healthy aging. It was formerly known as ChromaDex Corporation and adopted the Niagen Bioscience name in 2025. Niagen Bioscience serves consumers and commercial customers in the United States and international markets through online sales, retail and distribution channels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.